Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper 1 – Gynaecological cancers

2560 - BAROCCO: A randomized phase II study of weekly paclitaxel vs. cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC)

Date

27 Sep 2019

Session

Proffered Paper 1 – Gynaecological cancers

Topics

Tumour Site

Ovarian Cancer

Presenters

Nicoletta Colombo

Citation

Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394

Authors

N. Colombo1, M.O. Nicoletto2, P. Benedetti Panici3, G. Tognon4, A. Bologna5, A.A. Lissoni6, A. DeCensi7, F. Tomao8, R. Fossati9, F. Tettamanzi10, E. Rulli9, F. Galli9, M. De Luca9, M.F. Alvisi9, R. Mancari11, M. Ratti4, A. Baldoni12, V. Torri10, E. Biagioli9

Author affiliations

  • 1 Gynecologic Oncology, Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 2 Oncologia Medica, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 3 Materno Infantile E Scienze Urologiche, Universita La Sapienza, 00185 - Rome/IT
  • 4 Ginecologia, ASST Spedali Civili di Brescia, Università degli Studi di Brescia, Brescia/IT
  • 5 Medical Oncology Unit, IRCCS– Arcispedale S. Maria Nuova, 42123 - Reggio Emilia/IT
  • 6 Ginecologia Oncologica, Azienda Ospedaliera S. Gerardo - Oncologia Medica, 20900 - Monza/IT
  • 7 Oncologia Medica, EO Ospedali Galliera, Genova/IT
  • 8 Materno Infantile E Scienze Urologiche, Universita La Sapienza, Rome/IT
  • 9 Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan/IT
  • 10 Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 - Milan/IT
  • 11 Gynecologic Oncology, Istituto Europeo di Oncologia, Milan/IT
  • 12 Oncologia Medica, Istituto Oncologico Veneto IRCCS, Padova/IT
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2560

Background

Hypoxia induced by antiangiogenic agents could cause a functional impairment of homologous recombination, thus sensitizing wild-type (wt) BRCA tumor cells to PARP inhibition. In a phase II study the combination of cediranib-olaparib increased progression free survival (PFS) in women with recurrent platinum sensitive OC with respect to olaparib.

Methods

123 patients were allocated in a 1:1:1 ratio to receive: 80 mg/m2 weekly paclitaxel up to 24 weeks (control), olaparib 600 mg tablet (300 mg twice daily) together with 20 mg cediranib daily (continuous schedule) or 20 mg cediranib given 5 days/week (intermittent schedule) until progression. PFS comparison between experimental schedules and the control arm (alpha one-sided 5%; power 80% to detect a HR of 0.5) was the primary objective.

Results

Median platinum-free interval was 1.8 mos, 59% of patients were pretreated with >3 chemotherapy lines. Median PFS for paclitaxel, the continuous, and the intermittent schedules were 3.1, 5.7, and 3.8 mos. Estimated HR for PFS in continuous arm vs control was 0.76 (90% CI: 0.49-1.17), p = 0.28 by log-rank test. HR for PFS in intermittent arm vs. control was 1.08 (90% CI: 0.71-1.64), p = 0.76 by log-rank test. In the subgroup gBRCA wt (n = 109) the median PFS for paclitaxel, the continuous, and the intermittent schedules were 2.1, 5.8 and 3.8 mos and HR for PFS in continuous arm vs control was 0.63 (95% CI: 0.36 to 1.10; p = 0.10). The toxicity profile of the study arms was as expected and similar between experimental arms. 11%, 18%, and 7% in control, continuous and intermittent arm discontinued treatment for adverse events. Five serious adverse drug reactions occurred and two of these were fatal: one in the control and one in the continuous arm.

Conclusions

The combination of cediranib and olaparib is effective in heavily pretreated PROC patients with the advantage of an oral administration and good tolerability. The continuous schedule of cediranib-olaparib showed a promising trend towards improved PFS in comparison with weekly paclitaxel particularly in the BRCA wt population.

Clinical trial identification

IRFMN-OVA-7289, EudraCT: 2016-003964-38, NCT03314740.

Editorial acknowledgement

Legal entity responsible for the study

Istituto di Ricerche Farmacologiche Mario Negri IRCCS.

Funding

AstraZeneca.

Disclosure

N. Colombo: Honoraria (self), Advisory / Consultancy: Roche/Genentech; Honoraria (self), Advisory / Consultancy: PharmaMar; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Tesaro; Advisory / Consultancy: Clovis Oncology; Advisory / Consultancy: Pfizer; Advisory / Consultancy: MSD Oncology; Advisory / Consultancy: BioCad; Advisory / Consultancy: Takeda. G. Tognon: Advisory / Consultancy: Amgen; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Roche; Speaker Bureau / Expert testimony, Research grant / Funding (institution): AstraZeneca; Speaker Bureau / Expert testimony: Tesaro. M. Ratti: Travel / Accommodation / Expenses: Tesaro Bio. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.